Welcome to Martinez, Manglardi, Diez-Arguelles & Tejedor, P.A.’s Celebrex page.

If you or someone you love has suffered side effects from the drug Celebrex, you may be entitled to compensation. Celebrex has been found to more than double the risk of heart attack in patients taking the medication. At Martinez, Manglardi, Diez-Arguelles & Tejedor, P.A., we are committed to protecting the rights of those injured by dangerous drugs, including Celebrex. For more than 17 years, we have helped Floridians receive over $100 million in favorable verdicts and settlements. Our team of skilled professionals is backed by leading technology that enables us to keep in touch with the legal community, legislative developments and our clients. In addition to litigating dangerous drug cases, we provide counsel on personal injury, wrongful death, motor vehicle crashes, product liability, medical malpractice, nursing home abuse, insurance contract disputes and theme park negligence claims. If you or someone you know took Celebrex to combat pain and instead suffered adverse health problems, we encourage you to contact our office today for a free evaluation of your claim.

Celebrex (celecoxib) is designed to reduce substances that cause inflammation, pain, and fever in the body. It is prescribed to treat osteoarthritis, rheumatoid arthritis, and other painful conditions. Vioxx, Celebrex and Bextra are all part of the family of COX-2 inhibitor drugs. While older, non prescription drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs) cause stomach problems, the COX-2 inhibitor drug family provides pain relief without causing gastric distress. While being easier on the stomach, serious side effects have been found in Celebrex including an increased risk of blood clots, heart attacks and strokes. The Adenoma Prevention with Celecoxib (APC) trial was conducted to investigate the possible cancer-prevention properties of Celebrex in people at high risk of developing colon cancer. While conducting this new study, it was found that patients taking 400 mg or 800 mg of Celebrex daily were subject to an approximately 2.5-fold increase in their risk of having a major fatal or nonfatal heart attack when compared with those patients taking a placebo. Because of these findings the National Cancer Institute, the trial sponsor, abruptly stopped the study. In September of 2004, Vioxx was removed from the market. Now a recent study indicates that Celebrex's risk of heart attack and stroke are even greater than that of Vioxx.

While the FDA and outside advisory committees study whether Celebrex’s risks outweigh its benefits, Pfizer will continue to reap enormous revenue from the sale of this potentially fatal product. How many more people will be injured or die during this time? If you have experienced any side effects while taking, or subsequent to taking Celebrex, the time to protect your rights is now. Martinez, Manglardi, Diez-Arguelles & Tejedor, P.A.’s verdicts and settlements are among the highest in Florida. Remember, we represent our clients’ interests – not those of pharmaceutical giants or insurance companies. Let us help you make informed decisions about your claim. We’ll provide a free consultation in your home, at the hospital or in our offices. Contact us today in Orlando at (407) 381-4123, or in Kissimmee, (407) 846-2240 or via our online contact form.

Recent Celebrex and COX-2 Drug Developments

FDA Panel: Unanimous Vote on Celebrex Heart Risks (February 18, 2005)
The FDA’s arthritis and drug safety advisory committees concluded three days of meetings to assess the risks of three popular Cox-2 inhibitors. While Celebrex was unanimously voted to pose increased risk for heart problems, it was decided that the drug should remain on the market because the benefits outweighs the dangers.

FDA Panel Voting on Future of Pain Drugs (February 18, 2005)
An FDA advisory panel is set to decide on February 18th on which of the COX-2 inhibitors, if any, offer enough benefits to justify the risks. The FDA will consider the recommendations, and usually follows its committees' advice. The FDA is in hearings which includes evidence from drug makers and scientists in response to mounting concerns about Cox-2s including Pfizer’s Celebrex and Bextra. A scientist from the FDA's office of drug safety has been banned from presenting new information regarding the leading pain medication.

Director of Public Health Research Group (HRG) Testifies before FDA (February 17, 2005)
In hearings before the FDA Arthritis and Drug Safety Advisory Committees, Sidney M. Wolfe, M.D. Director HRG testifies on the dangers concerning COX-2 Drugs.